PT - JOURNAL ARTICLE AU - DeJonge, Peter AU - Gummin, David AU - Titelbaum, Nicholas AU - Meiman, Jonathan TI - Description of Kratom Exposure Events in Wisconsin as Reported to the Wisconsin Poison Center — January 1, 2010–September 1, 2022 AID - 10.1101/2023.01.03.22284038 DP - 2023 Jan 01 TA - medRxiv PG - 2023.01.03.22284038 4099 - http://medrxiv.org/content/early/2023/01/05/2023.01.03.22284038.short 4100 - http://medrxiv.org/content/early/2023/01/05/2023.01.03.22284038.full AB - Background Consumption of kratom (Mitragyna speciosa), an herbal substance, can result in adverse health effects. We characterized kratom-associated adverse events in Wisconsin to provide pertinent recommendations for clinicians and public health practitioners.Methods Using Wisconsin Poison Center (WPC) data, we searched for and summarized all records associated with exposure to “kratom”, “electronic delivery device containing kratom”, or “mitragyna” during January 1, 2010–September 1, 2022.Results Kratom-associated exposure calls to WPC increased 3.75 times during 2016–2020. Among all 59 calls, 26 (44.1%) reported concomitant use of another substance, agitation was the most common symptom reported (23, 39%), and 7 persons required critical care. Three unintentional ingestions were reported in infants aged <2 years.Discussion Kratom-associated exposure calls to WPC have been generally increasing in frequency since 2011. Wisconsinites who choose to use kratom might benefit from education regarding health risks and safe storage practices to avoid unintentional pediatric exposure.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This activity was reviewed by the U.S. Centers for Disease Control and Prevention (CDC) and was conducted consistent with applicable federal law and CDC policy. See e.g., 45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. section 241(d); 5 U.S.C. section 552a; 44 U.S.C. section 3501 et seq.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll de-identified data produced in the present study are available upon reasonable request to the authors.